Teva Pharmaceuticals, the U.S. branch of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has released interim findings from its Phase 4 IMPACT-TD Registry study. This large-scale study sheds light on the differences in tardive dyskinesia (TD) among patients with psychotic versus mood disorders, and provides real-world insights into treatment outcomes using AUSTEDO® XR® (deutetrabenazine) extended-release tablets and AUSTEDO (deutetrabenazine) twice-daily tablets. Additional interim data from a patient-reported survey of AUSTEDO XR are also being shared at the 2024 Psych Congress held October 29 to November 2 in Boston, MA.
“Tardive dyskinesia is both underdiagnosed and poorly understood, significantly impacting patients’ lives,” noted Dr. Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer at Teva. “Our commitment to improving patient outcomes drives us to deepen our understanding of TD and find ways to enhance the daily lives of those affected.”
The IMPACT-TD Registry is a three-year, two-part longitudinal observational study examining TD’s progression, patient quality of life, and treatment results with AUSTEDO XR and AUSTEDO. Patients with TD were included in the study, even without an official TD diagnosis.
Key findings from the IMPACT-TD study include:
- Diagnosis Disparity: A lower percentage of patients with psychotic disorders had a formal TD diagnosis compared to those with mood disorders (36% vs. 50%), despite similar mean AIMS scores (8.7 vs. 8.0), a longer average time since symptom recognition (5.5 vs. 3.8 years), and more prolonged antipsychotic use (16 vs. 10 years).
- Demographic Differences: Psychotic disorder patients (n=135) were, on average, younger (mean age 48 vs. 55.5), more likely to be Black or African American (36% vs. 9%), and male (62% vs. 38%) compared to those with mood disorders (n=141).
- Quality of Life Impact: Clinicians reported that TD had a moderate or severe impact on 86% of patients with psychotic disorders and 80% of those with mood disorders.
Dr. Rakesh Jain, Clinical Professor of Psychiatry at Texas Tech University School of Medicine, emphasized the importance of early detection and treatment for TD in people with psychotic disorders, noting the rise in antipsychotic use and the consequent need to monitor for TD symptoms.
Teva also presented findings from a non-interventional survey exploring patients’ real-world experiences with AUSTEDO XR, which included adults with TD or Huntington’s disease (HD) chorea. The interim analysis of 131 respondents found:
- 87% reported overall satisfaction with AUSTEDO XR.
- 74% observed improvement in their involuntary movements.
- Over 76% agreed that reduced movements improved their social comfort and emotional well-being, and more than half reported improved physical health and life balance.
- Nearly all respondents (98%) found AUSTEDO XR easy to incorporate into their daily routine, with 95% indicating they would continue using it.
Approximately 57 million Americans are affected by mental illness, with 14 million facing serious mental health conditions. TD, a chronic movement disorder affecting one in four patients on certain psychiatric medications, can disrupt everyday activities like eating, talking, and walking, affecting both physical and emotional health.
